Health Catalyst, Inc Common Stock (HCAT) Stock
NASDAQ · HCAT
Key stats
- Market cap
- $108.90M
- Price / Earnings ratio
- -0.5x
- EPS (TTM)
- -$2.84
- Volume
- Loading
- 52-week high
- $3.36
- 52-week low
- $0.96
Source: third-party data provider, as of November 13, 2026
Compare with HCAT
Recent news

MarketBeat
Health Catalyst Q2 Earnings Call Highlights
HCATAugust 7, 2026
MarketBeat
Health Catalyst Q2 Earnings Call Highlights
HCAT

Zacks Investment Research
Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics
HCATAugust 6, 2026
Zacks Investment Research
Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics
HCAT

Zacks Investment Research
Health Catalyst (HCAT) Beats Q2 Earnings and Revenue Estimates
HCATAugust 6, 2026
Zacks Investment Research
Health Catalyst (HCAT) Beats Q2 Earnings and Revenue Estimates
HCAT

MarketBeat
Health Catalyst Investors Approve Directors, Pay; Board Declassification Fails
HCATJuly 16, 2026
MarketBeat
Health Catalyst Investors Approve Directors, Pay; Board Declassification Fails
HCAT
Technical indicators
- RSI 14
- 37.98
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.05
- MACD histogram
- -0.02
- SMA 50
- $1.70
- Price below SMA 50
- EMA 50
- $1.68
- Price below EMA 50
- SMA 200
- $1.68
- Price below SMA 200
- EMA 200
- $1.80
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Strong Sell0
Sell0
Hold1
Buy0
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
373M246M123M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
1B680M340M0
Revenue to Profit
2025$311.1M
Revenue$0.0
Cost of revenue$151.7M
Gross profit$0.0
Operating expenses$-178.0M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Health Catalyst Q2 Earnings Call Highlights
HCATAugust 7, 2026
MarketBeat
Health Catalyst Q2 Earnings Call Highlights
HCAT

Zacks Investment Research
Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics
HCATAugust 6, 2026
Zacks Investment Research
Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics
HCAT

Zacks Investment Research
Health Catalyst (HCAT) Beats Q2 Earnings and Revenue Estimates
HCATAugust 6, 2026
Zacks Investment Research
Health Catalyst (HCAT) Beats Q2 Earnings and Revenue Estimates
HCAT

MarketBeat
Health Catalyst Investors Approve Directors, Pay; Board Declassification Fails
HCATJuly 16, 2026
MarketBeat
Health Catalyst Investors Approve Directors, Pay; Board Declassification Fails
HCAT

MarketBeat
Health Catalyst Q1 Earnings Call Highlights
HCATMay 12, 2026
MarketBeat
Health Catalyst Q1 Earnings Call Highlights
HCAT

Zacks Investment Research
Health Catalyst (HCAT) Q1 Earnings and Revenues Surpass Estimates
HCATMay 11, 2026
Zacks Investment Research
Health Catalyst (HCAT) Q1 Earnings and Revenues Surpass Estimates
HCAT

Zacks Investment Research
Compared to Estimates, Health Catalyst (HCAT) Q1 Earnings: A Look at Key Metrics
HCATMay 11, 2026
Zacks Investment Research
Compared to Estimates, Health Catalyst (HCAT) Q1 Earnings: A Look at Key Metrics
HCAT

Zacks Investment Research
Seeking Clues to Health Catalyst (HCAT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
HCATMay 7, 2026
Zacks Investment Research
Seeking Clues to Health Catalyst (HCAT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
HCAT

Zacks Investment Research
Health Catalyst (HCAT) Reports Q4 Earnings: What Key Metrics Have to Say
HCATMarch 12, 2026
Zacks Investment Research
Health Catalyst (HCAT) Reports Q4 Earnings: What Key Metrics Have to Say
HCAT

Zacks Investment Research
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
HCATMarch 12, 2026
Zacks Investment Research
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
HCAT
About Health Catalyst, Inc Common Stock
No description available.
SectorHealthcare
IndustryHealth Information Services
Employees1,200
CEOMr. Benjamin Albert
IPO DateJul 24, 2019
HeadquartersSouth Jordan, UT
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Benjamin Albert | CEO & Director | 1973 |
| Mr. Jason Alger | Chief Financial Officer | 1984 |
| Mr. Ryan Barry | Chief Operating Officer of Professional Services | — |
| Mr. Benjamin Landry | General Counsel & Secretary of the Board | 1982 |
| Mr. Kyle J. Salyers | Chief Strategy Officer & Senior VP of Corporate Development | — |
| Ms. Carrie Kozlowski OT | Chief Marketing Officer | — |
| Mr. Jeffrey P. Selander | Senior Vice President of International | — |
| Ms. Holly Rimmasch | Senior VP & Chief Clinical Officer | — |
| Ms. Sadiqa Mahmood D.D.S., M.P.H. | GM & Senior VP of Life Sciences Business | — |
| Kristen Berry | Senior Vice President of Public Relations | — |
Fundamentals
Valuation
Price-to-sales ratio0.36
Price-to-book value0.75
Profitability
Return on Equity-128.00%
Return on Assets-54.00%
Return on Sales-69.00%
Gross margin (latest quarter)42.71%
EBITDA$-140.26M
Trading
Average volume365,941
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 37.98
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.05
- MACD histogram
- -0.02
- SMA 50
- $1.70
- Price below SMA 50
- EMA 50
- $1.68
- Price below EMA 50
- SMA 200
- $1.68
- Price below SMA 200
- EMA 200
- $1.80
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Hold
0% Buy
100% Hold
0% Sell
Analyst price target
- Low
- $1.80
- Average
- $1.80
- High
- $1.80
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.4 | -3.8 | ||||||||||
| 2022 | -26.0 | -10.9 | -1.6 | -39.8 | -12.9 | +3.3 | +8.7 | -29.4 | -17.7 | -14.0 | +15.9 | -0.1 |
| 2023 | +33.8 | +1.0 | -18.5 | +6.1 | -13.3 | +10.9 | +14.8 | -18.4 | -13.7 | -26.3 | -0.7 | +21.7 |
| 2024 | +7.1 | -15.8 | -6.6 | -14.6 | +5.1 | -0.6 | +21.4 | +1.1 | +12.3 | -3.5 | +14.7 | -21.6 |
| 2025 | -23.3 | -14.6 | -1.5 | -8.8 | -4.8 | -0.5 | -9.9 | -3.7 | -16.2 | +14.9 | -4.8 | -17.9 |
| 2026 | -5.7 | -29.6 | -24.4 | +7.8 | -4.8 | +43.2 | +1.0 | -25.8 | +1.2 | -0.6 | -8.9 |
Compare stocks
Market cap
$108.90M
-
-
-
Price / Earnings ratio
-0.50
-
-
-
Price / Sales ratio
0.36
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
365,941
-
-
-
Earnings per share
$-2.84
-
-
-



